Literature DB >> 21499098

Multiple sclerosis: current treatment algorithms.

Jordi Río1, Manuel Comabella, Xavier Montalban.   

Abstract

PURPOSE OF REVIEW: Multiple sclerosis (MS) is an inflammatory autoimmune disorder of the central nervous system. Currently, there are different formulations approved for MS treatment and others are in different stages of investigation or awaiting approval by federal agencies. RECENT
FINDINGS: All of these medications have demonstrated partial efficacy along with different side-effect profiles. Nevertheless, many patients continue to experience disease activity while on treatment, and recommendations have been made on how the success of therapy in an individual patient can be assessed.
SUMMARY: The option of individualized optimal treatment is progressively more complicated due to the growth of our knowledge about the natural behavior of MS and its different types and stages, the variety of different therapies, their strength and weaknesses, and their serious and sometimes life-threatening side-effects. In this review, we will summarize current algorithms and treatment options and also address clinical challenges we regularly face in arriving at treatment choices for our patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21499098     DOI: 10.1097/WCO.0b013e328346bf66

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  19 in total

1.  Health insurance affects the use of disease-modifying therapy in multiple sclerosis.

Authors:  Guoqiao Wang; Ruth Ann Marrie; Amber R Salter; Robert Fox; Stacey S Cofield; Tuula Tyry; Gary R Cutter
Journal:  Neurology       Date:  2016-06-29       Impact factor: 9.910

2.  Interferon β-1a therapy for multiple sclerosis during pregnancy: an unresolved issue.

Authors:  Aldrin Anthony Dung Dung; Akhila Kumar Panda
Journal:  BMJ Case Rep       Date:  2014-04-07

3.  Dynamic Learning of Patient Response Types: An Application to Treating Chronic Diseases.

Authors:  Diana M Negoescu; Kostas Bimpikis; Margaret L Brandeau; Dan A Iancu
Journal:  Manage Sci       Date:  2017-08-21       Impact factor: 4.883

Review 4.  ["Time is brain" in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy].

Authors:  R Linker; B-A Kallmann; C Kleinschnitz; P Rieckmann; M Mäurer; S Schwab
Journal:  Nervenarzt       Date:  2015-12       Impact factor: 1.214

5.  Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial.

Authors:  Jan Dörr; Stephanie Ohlraun; Horst Skarabis; Friedemann Paul
Journal:  Trials       Date:  2012-02-08       Impact factor: 2.279

6.  Pediatric multiple sclerosis-a challenging demyelinating disease: case report and brief review of the literature.

Authors:  Regina Célia Ajeje Pires de Albuquerque; Raquel Siqueira Leonel de Paula; Manuelina Mariana Capellari Macruz Brito; José Roberto Lopes Ferraz Filho; Lucas Crociati Meguins
Journal:  Case Rep Pediatr       Date:  2012-07-11

7.  Serum biomarker gMS-Classifier2: predicting conversion to clinically definite multiple sclerosis.

Authors:  Georgina Arrambide; Carmen Espejo; Jennifer Yarden; Ella Fire; Larissa Spector; Nir Dotan; Avinoam Dukler; Alex Rovira; Xavier Montalban; Mar Tintore
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

8.  Can we prevent or treat multiple sclerosis by individualised vitamin D supply?

Authors:  Jan Dörr; Andrea Döring; Friedemann Paul
Journal:  EPMA J       Date:  2013-01-29       Impact factor: 6.543

9.  Current options for the treatment of optic neuritis.

Authors:  John H Pula; Christopher J Macdonald
Journal:  Clin Ophthalmol       Date:  2012-07-31

10.  Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.

Authors:  Mireya Fernández-Fournier; Antonio Tallón-Barranco; Beatriz Chamorro; Patricia Martínez-Sánchez; Inmaculada Puertas
Journal:  BMC Neurol       Date:  2015-08-19       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.